Opsumit: Ph III MAESTRO data

Top-line data from the double-blind, international Phase III MAESTRO trial in 226 patients with PAH due to Eisenmenger syndrome in the intent-to-treat (ITT) population showed that once-daily 10 mg oral Opsumit missed the

Read the full 335 word article

User Sign In